Abstract
A validated disease-specific symptom-assessment tool for eosinophilic esophagitis (EoE) has yet to be approved by regulatory authorities for use in clinical trials. Relevant end points for daily practice include EoE-related symptoms and esophageal eosinophilic inflammation. Endoscopic features should also be taken into account when establishing a therapy plan. A reasonable clinical goal is to achieve a reduction in EoE-related symptoms and esophageal eosinophilic inflammation. Evidence is increasing to support an anti-inflammatory maintenance therapy, as this can reduce esophageal remodeling. In EoE patients in clinical remission, annual disease monitoring with symptom, endoscopic, and histologic assessments of sustained treatment response is recommended.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 329-344 |
| Number of pages | 16 |
| Journal | Gastroenterology Clinics of North America |
| Volume | 43 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jun 2014 |
Funding
Disclosures: A.M. Schoepfer received consulting fees and/or speaker fees and/or research grants from AstraZeneca , AG, Switzerland, Aptalis Pharma , Inc, Dr Falk Pharma , GmbH, Germany, Glaxo Smith Kline , AG, Nestlé S. A. , Switzerland, and Novartis , AG, Switzerland. D.A. Katzka has no relevant financial, professional, or personal relationships to disclose. I. Hirano received consulting fees and/or speaker fees and/or research grants from Meritage Pharma , Inc, Aptalis Pharma , Inc, and Receptos, Inc .
Keywords
- Dysphagia
- Eosinophilic esophagitis
- Gastroesophageal reflux disease
- Patient-reported outcomes
- Treatment end points
ASJC Scopus subject areas
- Gastroenterology